Long-Term Survival in a Patient with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil as Late-Line Chemotherapy: A Case Report.

Autor: Karabulut B; Department of Medical Oncology, Özel İzmir Kent Hospital, Izmir, Turkey., Çakar B; Department of Medical Oncology, Ege University, Izmir, Turkey.
Jazyk: angličtina
Zdroj: Case reports in oncology [Case Rep Oncol] 2024 Jun 07; Vol. 17 (1), pp. 630-639. Date of Electronic Publication: 2024 Jun 07 (Print Publication: 2024).
DOI: 10.1159/000535202
Abstrakt: Introduction: Although long-term survival in patients with metastatic colorectal cancer (mCRC) is limited, treatments for third-line and later treatment are now recommended. We describe a patient who achieved long-term survival when they received third-line treatment with trifluridine/tipiracil (FTD/TPI).
Case Presentation: The woman who was 52 years old at diagnosis of adenocarcinoma of the right colon (T3/N0/M1) with metastases to the lung, liver, ovary, and other soft tissues received first-line fluoropyrimidine-based chemotherapy (FOLFOX/FOLFIRI plus bevacizumab) intermittently for approximately 8.5 years with generally stable disease, and second-line FOLFIRI plus radiotherapy. After progression on second-line therapy, the patient initiated treatment with FTD/TPI 35 mg/m 2 twice daily on days 1-5 and 8-12 of each 28-day cycle. She received a total of 38 cycles of FTD/TPI over a period of 34 months achieving a partial response, maintained performance status, and improved quality of life. Neutropenia was successfully managed with FTD/TPI dose delays or reductions.
Conclusion: This heavily pre-treated patient with mCRC demonstrated impressive long-term survival and maintenance of good quality of life with FTD/TPI treatment.
Competing Interests: Bülent Karabulut has no conflicts to report. Burcu Çakar has no conflicts to report.
(© 2024 The Author(s). Published by S. Karger AG, Basel.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje